Hatte heute nach einer Podiumsdiskussion bei einem netten Empfang (über der Skyline von Berlin) ein interessantes Gespräch. Die kleinen Firmen erscheinen mittlerweile billige Übernahmekandidaten zu sein. Man sprach von "Schnäppchen".
Top-News
Würde nun mal Bio-Techs empfehlen.....
Beiträge:
6
Zugriffe: 352 / Heute: 1
Zugriffe: 352 / Heute: 1
Rhein-Bio war nur der Anfang.
Bei den großen Pharma-Buden wird wirklich darüber nachgedacht, die nunmehr recht billigen Aufsteiger aufzukaufen.
Habe diese Info - man mag mich nun Pusher nennen (aber wer mich mit meinen inzwischen eher sporadischen Postings kennt) - bei einem recht netten Bankett mitbekommen. Dabei waren auch Leute von dicken deutschen Chemiefirmen anwesend.
Prösterchen!!!!!
Bei den großen Pharma-Buden wird wirklich darüber nachgedacht, die nunmehr recht billigen Aufsteiger aufzukaufen.
Habe diese Info - man mag mich nun Pusher nennen (aber wer mich mit meinen inzwischen eher sporadischen Postings kennt) - bei einem recht netten Bankett mitbekommen. Dabei waren auch Leute von dicken deutschen Chemiefirmen anwesend.
Prösterchen!!!!!
Ich WERDE warten !!
Ich WERDE warten !!
Ich WERDE warten !!
Alles andere ist Wahnsinn !!
Ich WERDE warten !!
Ich WERDE warten !!
Alles andere ist Wahnsinn !!
die Dinger sind im Schlussverkauf zu haben. Aber wer es nicht glaubt?
z.B.Genzyme Molecular Oncology GZMO,Tochtergesellschaft von Genzyme, heute plus 57% weil sie auf einer Tagung ein neues Impfmittel zur Schrumpfung von Tumoren,besonders in der Niere und bei Melanom, vorstellen .
Genzyme Molecular Oncology's study examined whether a vaccine produced from the fusion of melanoma cells and dendritic cells could prompt an immune response to stop cancer tumor growth. The results indicate that treatment with this electrofused vaccine is capable of stopping tumor growth and that the approach could potentially be applied to a wide range of cancer types. More specifically, the pre-clinical study demonstrates that high levels of tumor rejection can be achieved in both kidney and melanoma tumor models. This anti-tumor effect also is accompanied by a T-cell response directed against several tumor proteins. "Cell fusion technology is significant because it eliminates the need to identify specific cancer proteins for these vaccines," stated William Siders, Ph.D., research scientist with Genzyme Corp. and the presenter of the electrofusion data at the conference. "Instead, it incorporates an entire menu of proteins found on the cancer tumor that will provide targets to the immune system." Genzyme Molecular Oncology has a leading intellectual property position around the fusion vaccines. In addition, the electrofusion process expands Genzyme Molecular Oncology's current breadth of expertise in this area, building on its trials in breast cancer, kidney cancer and melanoma that utilize a chemical fusion method. "We're very excited about starting the new fusion cell trials and proud of our expanding clinical program in immunotherapy," added Gail Maderis, president of Genzyme Molecular Oncology. "We now have five cancer vaccine trials that will be completed this year, and will begin a trial using this electrofusion approach in kidney cancer within a couple of months. Fusion technology complements our antigen specific vaccines and allows us to address cancers where antigens are not yet known or well understood." The planned trial using the electrofusion method will provide Genzyme Molecular Oncology with patient safety and efficacy data, as well as a comparison of the two processes -- chemical fusion and electrofusion -- for producing cell fusion vaccines.
Das ist Zukunft!Und Phantasie!
naja ,kann mir schon denken,dass Karlchen die Werte vom Nemax meint,vielleicht Morphosys oder Medigene?
Genzyme Molecular Oncology's study examined whether a vaccine produced from the fusion of melanoma cells and dendritic cells could prompt an immune response to stop cancer tumor growth. The results indicate that treatment with this electrofused vaccine is capable of stopping tumor growth and that the approach could potentially be applied to a wide range of cancer types. More specifically, the pre-clinical study demonstrates that high levels of tumor rejection can be achieved in both kidney and melanoma tumor models. This anti-tumor effect also is accompanied by a T-cell response directed against several tumor proteins. "Cell fusion technology is significant because it eliminates the need to identify specific cancer proteins for these vaccines," stated William Siders, Ph.D., research scientist with Genzyme Corp. and the presenter of the electrofusion data at the conference. "Instead, it incorporates an entire menu of proteins found on the cancer tumor that will provide targets to the immune system." Genzyme Molecular Oncology has a leading intellectual property position around the fusion vaccines. In addition, the electrofusion process expands Genzyme Molecular Oncology's current breadth of expertise in this area, building on its trials in breast cancer, kidney cancer and melanoma that utilize a chemical fusion method. "We're very excited about starting the new fusion cell trials and proud of our expanding clinical program in immunotherapy," added Gail Maderis, president of Genzyme Molecular Oncology. "We now have five cancer vaccine trials that will be completed this year, and will begin a trial using this electrofusion approach in kidney cancer within a couple of months. Fusion technology complements our antigen specific vaccines and allows us to address cancers where antigens are not yet known or well understood." The planned trial using the electrofusion method will provide Genzyme Molecular Oncology with patient safety and efficacy data, as well as a comparison of the two processes -- chemical fusion and electrofusion -- for producing cell fusion vaccines.
Das ist Zukunft!Und Phantasie!
naja ,kann mir schon denken,dass Karlchen die Werte vom Nemax meint,vielleicht Morphosys oder Medigene?
Ne, Morphosys it nicht. Habe die Dinger bei 360 und 380 rausghauen. Habe noch - zugegebenermaßen einige Medigene (mit 50% Verlust). Ansonsten gibt es nur noch "Exoten" in meinem Depot - einer davon führt gegenwärtig eine Kapitalerhöhung durch - werde mal sehen, ob ich da mitzeichne.
Es gibt keine neuen Beiträge.
